Omeprazole Articles
AstraZeneca opts to buy out rights to certain products from US Merck & Co JV for $647 million
2 March 2010
AstraZeneca sees strong earnings and revenue growth in2009 but a slowdown in 4th qtr
28 January 2010
US FDA warns against use of PPI Prilosec with Plavix
18 November 2009
Americans with heartburn paying too much for Nexium's 'Purple Pill,' claims Consumer Reports
30 October 2009
AGI Thera terminates omeprazole deal with Axcan
14 August 2009
Dr Reddy's gets favorable Prilosec ruling
23 March 2009
P&G looking to sell pharma operations
16 February 2009
AstraZeneca's net income slips 1.6% in 4th qtr as generic competition starts to bite
9 February 2009
FDA setback for S-P and Santarus' Zegerid
19 January 2009
Pozen's coated aspirin tablet shows less GI damage
17 November 2008
China Sky One has 11 generics in pipeline
21 July 2008
Santarus developing new Zegerid formulation
2 June 2008
S-P files Zegrid OTC NDA with FDA
17 March 2008
Perrigo begins shipping omeprazole
10 March 2008
Merck & Co sells JV products to AZ
10 March 2008
Zegerid launched in P Rico and Virgin Is
25 February 2008
Bentley's generic Losec wins European approval
18 February 2008
Dr Reddy's sees 850M Rs loss in Q3 of FY 2008
4 February 2008
Cogentus initiates Ph III CGT-2168 trial
28 January 2008
Final OK for OTC omeprazole, and Perrigo ups guidance
17 December 2007
"No cardiac risks with AstraZeneca PPIs," FDA
17 December 2007
Santaurus and GSK in licensing deal
10 December 2007
EPO upholds AstraZeneca's MUPS PPI patents
26 November 2007
Meda to acquire Recip for $407M+
5 November 2007
R&D costs double AGI's 1st-half loss
24 September 2007
Santarus gets $5M milestone form S-P
3 September 2007
US Court of Appeals endorses FDA pre-emption
3 September 2007
Domestic vs JV drug prices in China differ
20 August 2007
Mylan wins generic omeprazole case
11 June 2007
Schwarz' sales drop 6.2% in 1st qtr of 2007
7 May 2007
AstraZeneca's CEO reviews Japan ops
5 March 2007
AGI finalizing US NDA plan for arverapamil
26 February 2007
Canada: new formulary for new year - Ontario introducing reform
15 January 2007
Dr Reddy's to commercialize two Torrent drugs in Russia
11 December 2006
Canada's generic drug firms greet court ruling
13 November 2006
Schwarz back on track
6 November 2006
AGI Thera signs $19M deal with Axcan on omeprazole
2 October 2006
Dr Reddy's boosted by acquisitions
12 June 2006
Andrx' 1st-qtr 15% revenue fall, loss better
15 May 2006
Schwarz's 1st-qtr sales up 4% to 274M euros
8 May 2006
Santarus launches Zegerid caps in USA
3 April 2006
Japan recalculates eight drug ingredients due to high sales
27 February 2006
Schwarz Pharma's revenue up 4.6% in 2005
27 February 2006
AstraZeneca's 4th-qtr profit leaps 30% but firm admits thin pipeline
13 February 2006
Dr Reddy's of India sees revenues grow 25% and earnings rocket in fiscal third quarter
6 February 2006
Generics market takes off in France
6 February 2006
FDA warns against foreign Rx drugs
16 January 2006
TAP terminates sub-license deal with Santarus
16 January 2006
NZ subsidized Rxs rose 10.7% in FY2005
19 December 2005
Defending brand pharma against generic threats: study
5 September 2005
Poland and Russia boost Zentiva sales
15 August 2005
Schwarz beats 1st-half expectations
8 August 2005
US FDA accepts NDAs for INKP-102, indiplon and Zegrid chewable tablets; OKs Ph I PV-10 trials
1 August 2005
Editor's views on corporate and employee health
27 June 2005
EU fines AstraZeneca 60M euros over Losec
20 June 2005
Santarus gains on positive Zegerid trial data
20 June 2005
Mylan sees 12% drop in fourth-qtr profit
23 May 2005
Bentley gets UK OK for omeprazole
23 May 2005
French patent expiries to save1B euros by 2008
23 May 2005
Dr Reddy's Labs sees FY2005 profits slump
16 May 2005
Santarus files NDA with US FDA for Zegerid
9 May 2005
Schwartz Pharma boosted by US sales
9 May 2005
Portuguese Rx, Belgian generics market studies
25 April 2005
Santarus EPS drop of $3.30 in 2004
4 April 2005
Zentiva's 2004 EPS rockets 84.9%
21 March 2005
Schwarz Pharma beats forecasts but sales and profits down
28 February 2005
2004 "best-year in history" at Merck KGaA
21 February 2005
Strong 3rd-qtr for Takeda, as Actos and candesartan expand globally
21 February 2005
Santarus: Zegerid tablets trials a success
14 February 2005
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
